112 related articles for article (PubMed ID: 23547218)
1. Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: an open-label study.
Rigby WF; Mease PJ; Olech E; Ashby M; Tole S
J Rheumatol; 2013 May; 40(5):599-604. PubMed ID: 23547218
[TBL] [Abstract][Full Text] [Related]
2. Treatment of rheumatoid arthritis with biologic DMARDS (Rituximab and Etanercept).
Gashi AA; Rexhepi S; Berisha I; Kryeziu A; Ismaili J; Krasniqi G
Med Arch; 2014; 68(1):51-3. PubMed ID: 24783914
[TBL] [Abstract][Full Text] [Related]
3. A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis.
Yoo DH; Suh CH; Shim SC; Jeka S; Cons-Molina FF; Hrycaj P; Wiland P; Lee EY; Medina-Rodriguez FG; Shesternya P; Radominski S; Stanislav M; Kovalenko V; Sheen DH; Myasoutova L; Lim MJ; Choe JY; Lee SJ; Lee SY; Kwon TS; Park W
Ann Rheum Dis; 2017 Mar; 76(3):566-570. PubMed ID: 27624791
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients.
van Vollenhoven RF; Emery P; Bingham CO; Keystone EC; Fleischmann RM; Furst DE; Tyson N; Collinson N; Lehane PB
Ann Rheum Dis; 2013 Sep; 72(9):1496-502. PubMed ID: 23136242
[TBL] [Abstract][Full Text] [Related]
5. Long-term evaluation of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs.
Tanaka Y; Takeuchi T; Yamanaka H; Nanki T; Umehara H; Yasuda N; Tago F; Kitahara Y; Kawakubo M; Torii K; Hojo S; Kawano T; Imai T
Mod Rheumatol; 2023 Dec; 34(1):45-49. PubMed ID: 36680420
[TBL] [Abstract][Full Text] [Related]
6. Long-term clinical and radiological effectiveness and safety of ultralow doses of rituximab in rheumatoid arthritis: observational extension of the REDO trial.
den Broeder N; Verhoef L; de Man YA; Kok MR; Thurlings R; van der Weele W; van den Bemt BJ; van den Hoogen FH; van der Maas A; den Broeder AA
RMD Open; 2024 Apr; 10(2):. PubMed ID: 38599654
[TBL] [Abstract][Full Text] [Related]
7. Infection incidence, timing and dose dependency in rheumatoid arthritis patients treated with rituximab: a retrospective cohort study.
Veeken LD; Opdam MAA; Verhoef LM; Popa C; van Crevel R; den Broeder AA
Rheumatology (Oxford); 2024 May; 63(5):1246-1250. PubMed ID: 37410085
[TBL] [Abstract][Full Text] [Related]
8. The landscape of real-world evidence of rituximab utilization and clinical outcomes in patients with cancer, rheumatoid arthritis, and multiple sclerosis: A scoping review.
Li KH; Kaker M; Lau J; Noonan K; Zhang S; McDermott CL; Lockhart CM
J Manag Care Spec Pharm; 2024 May; 30(5):480-489. PubMed ID: 38701025
[TBL] [Abstract][Full Text] [Related]
9. Treat-to-target vs fixed interval retreatment strategy with rituximab in rheumatoid arthritis: a retrospective cohort study.
Schapink L; den Broeder N; den Broeder AA; Verhoef LM
Rheumatol Int; 2024 Jan; ():. PubMed ID: 38286887
[TBL] [Abstract][Full Text] [Related]
10. Rituximab is associated with worse COVID-19 outcomes in patients with rheumatoid arthritis: A retrospective, nationally sampled cohort study from the U.S. National COVID Cohort Collaborative (N3C).
Singh N; Madhira V; Hu C; Olex AL; Bergquist T; Fitzgerald KC; Huling JD; Patel RC; Singh JA
Semin Arthritis Rheum; 2023 Feb; 58():152149. PubMed ID: 36516563
[TBL] [Abstract][Full Text] [Related]
11. Safety and Tolerability of Rituximab in the Treatment of Systemic Sclerosis.
Garzanova LA; Ananyeva LP; Koneva OA; Desinova OV; Starovoytova MN; Ovsyannikova OB; Shayakhmetova RU; Glukhova SI
Dokl Biochem Biophys; 2024 Jun; ():. PubMed ID: 38861145
[TBL] [Abstract][Full Text] [Related]
12. Burden of non-serious infections during biological use for rheumatoid arthritis.
Bergmans B; Jessurun N; van Lint J; Murk JL; van Puijenbroek E; de Vries E
PLoS One; 2024; 19(2):e0296821. PubMed ID: 38377117
[TBL] [Abstract][Full Text] [Related]
13. Rituximab for Rheumatoid Arthritis.
Cohen MD; Keystone E
Rheumatol Ther; 2015 Dec; 2(2):99-111. PubMed ID: 27747531
[TBL] [Abstract][Full Text] [Related]
14. Impact of adverse drug reactions on the treatment pathways of early rheumatoid arthritis patients: a prospective observational cohort study.
Velthuis K; Poppelaars F; Ten Klooster PM; Vonkeman HE; Jessurun NT
Expert Opin Drug Saf; 2023; 22(8):753-762. PubMed ID: 36946179
[TBL] [Abstract][Full Text] [Related]
15. Immunodeficiency and autoimmunity during biological disease-modifying antirheumatic drug therapy.
Czekalska A; Majewski D; Puszczewicz M
Reumatologia; 2019; 57(4):214-220. PubMed ID: 31548748
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison.
Baji P; Péntek M; Czirják L; Szekanecz Z; Nagy G; Gulácsi L; Brodszky V
Eur J Health Econ; 2014 May; 15 Suppl 1(Suppl 1):S53-64. PubMed ID: 24832836
[TBL] [Abstract][Full Text] [Related]
17. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial.
Smolen JS; Emery P; Fleischmann R; van Vollenhoven RF; Pavelka K; Durez P; Guérette B; Kupper H; Redden L; Arora V; Kavanaugh A
Lancet; 2014 Jan; 383(9914):321-32. PubMed ID: 24168956
[TBL] [Abstract][Full Text] [Related]
18. Rituximab and tocilizumab for the treatment of rheumatoid arthritis.
González-Vacarezza N; Alemán A; González G; Pérez A
Int J Technol Assess Health Care; 2014 Jul; 30(3):282-8. PubMed ID: 25068763
[TBL] [Abstract][Full Text] [Related]
19. Safety of rituximab in the routine treatment of rheumatoid arthritis in Italy in patients refractory to anti-TNFa drugs: results from the observational retrospective-prospective RUBINO study.
Bazzichi L; Biasi D; Tinazzi E; Muratore M; Pellerito R; Russo R; Corsaro Santi M; De Sandre P; Epis O; Granata M; Kroegler B; Meschini C; Versace F; Astolfi C;
Reumatismo; 2014 Nov; 66(3):224-32. PubMed ID: 25376957
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of rituximab in elderly patients with rheumatoid arthritis enrolled in a French Society of Rheumatology registry.
Payet S; Soubrier M; Perrodeau E; Bardin T; Cantagrel A; Combe B; Dougados M; Flipo RM; Le Loët X; Shaeverbeke T; Ravaud P; Gottenberg JE; Mariette X
Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1289-95. PubMed ID: 25299001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
